Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02710669 · ClinicalTrials.gov registry record · Phase 1
New Formulations of Propafenone to Treat Atrial Fibrillation
A Phase 1 study, sponsored by Vanderbilt University.
- Terminated
- Registry status
- Phase 1
- Development phase
- 193
- Enrollment target
NCT02710669 is a Phase 1 study that was terminated before completion, run by Vanderbilt University. The registered enrollment target is 193 participants.
The verdict
NCT02710669, a Phase 1 study, was terminated before completion, sponsored by Vanderbilt University.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 193 participants
- Enrollment target
Study Summary
Propafenone is a currently used medicine to treat atrial fibrillation and is a mixture of two compounds, (R)-propafenone and (S)-propafenone. In this study, the investigators will randomize participants to (R)-propafenone, (S)-propafenone, or placebo.
Interventions
- DRUG Placebo
- DRUG (R)-propafenone
- DRUG (S)-Propafenone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 193 participants |
| Start Date | 2016-10 |
| Est. Completion | 2020-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02710669
The ClinicalTrials.gov registry entry for NCT02710669 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 193 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt University, which has 430 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02710669 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02710669 about?
NCT02710669 is a clinical study titled "New Formulations of Propafenone to Treat Atrial Fibrillation". Propafenone is a currently used medicine to treat atrial fibrillation and is a mixture of two compounds, (R)-propafenone and (S)-propafenone. In this study, the investigators will randomize participants to (R)-propafenone, (S)-propafenone, or placebo.
What is the current status of trial NCT02710669?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 193 participants. The study started on 2016-10. Estimated completion is 2020-04.
What interventions are being tested in trial NCT02710669?
The interventions under investigation include: Placebo (DRUG), (R)-propafenone (DRUG), (S)-Propafenone (DRUG).
Who is sponsoring clinical trial NCT02710669?
This trial is sponsored by Vanderbilt University, which has 430 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.